Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma

Ann Oncol. 2009 Feb;20(2):393-4. doi: 10.1093/annonc/mdn729.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Blood Pressure / drug effects
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Confidence Intervals
  • Disease Progression
  • Drug Administration Schedule
  • Humans
  • Hypertension / drug therapy*
  • Kidney Neoplasms / pathology*
  • Middle Aged
  • Proteinuria / chemically induced
  • Survival Analysis
  • Time Factors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab